drugset / Trial / NCT04655365
Detecting Metastases by PyL PET/CT in Subjects Starting Enzalutamide for Untreated Castration Resistant Prostate Cancer.
Phase 2
Active not recruiting
50 enrolled
CHU de Quebec-Universite Laval
Astellas Pharma Europe Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
This study aimed to evaluate the diagnostic performance of 18F-DCFPyL (PyL) PET/CT in subjects presenting not previously treated for castration resistant prostate cancer and showing negative or equivocal findings per institutional standard of care conventional imaging
Timeline
- Start
- 2022-03-22
- Primary completion
- 2025-11-01
- Completion
- 2026-09-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | Enzalutamide | Other / unclassified | 160 mg | Oral |